Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP002 in Relapsed or Refractory PMBCL
NCT04600947Phase 2Unknown
- Sponsor
- Taizhou Houde Aoke Technology
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LP002 in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Taizhou Houde Aoke Technology. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
LP002
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04600947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04600947.